• Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more